What is Evommune?
Evommune is dedicated to pioneering advanced immunology research to create targeted treatments for chronic inflammatory diseases. The company's focus is on addressing the underlying drivers of these conditions, aiming to provide therapeutic solutions that go beyond mere symptom management. With a pipeline designed for diseases where current treatment options are limited, Evommune is positioned to make a significant impact on patient outcomes in the biotechnology sector.
How much funding has Evommune raised?
Evommune has raised a total of $185M across 3 funding rounds:
Angel/Seed
$12.5M
Series B
$57.5M
Series C
$115M
Angel/Seed (2020): $12.5M with participation from PIVOTAL BIOVENTURE PARTNERS LLC
Series B (2023): $57.5M led by Symbiosis Group, Arix Bioscience, and Verition Fund Management
Series C (2024): $115M supported by Longwood Fund, Andera Partners, ADAR1 Capital Management, RA Capital Management, Marshall Wace, RTW Investments, Beiersdorf, Avego, Amplitude Ventures, Verition Fund Management, FemHealth Ventures, Pivotal Bioventure Partners, B Capital Group, and Sectoral Asset Management
Key Investors in Evommune
Longwood Fund
Longwood Fund is a venture capital firm that creates and invests in science-based companies focused on developing innovative solutions for significant medical challenges, actively collaborating in building companies.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, aiming to partner with innovators to bring ideas from the lab to the clinic.
Arix Bioscience
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences, providing capital, expertise, and global networks.
What's next for Evommune?
The recent major enterprise-level funding and strategic investment indicate a pivotal growth phase for Evommune. This capital infusion is expected to accelerate the advancement of its clinical pipeline, potentially enabling further research and development, expanding its operational capacity, and supporting regulatory submissions. The company's strategic focus on unmet needs in chronic inflammatory diseases suggests a trajectory towards significant clinical milestones and potential market entry, positioning it for future expansion and partnerships within the life sciences industry.
See full Evommune company page
